Background:
Dementia with Lewy body (DLB) diagnostic criteria define “indicative” and “supportive” biomarkers, but clinical practice patterns are unknown.
Methods:
An anonymous survey querying clinical use of diagnostic tests/biomarkers was sent to 38 center of excellence investigators. The survey included “indicative” biomarkers (dopamine transporter scan, myocardial scintigraphy, polysomnography), “supportive” biomarkers [magnetic resonance imaging (MRI)], positron emission tomography, or single-photon emission computed tomography perfusion/metabolism scans, quantitative electroencephalography), and other diagnostic tests (neuropsychological testing, cerebrospinal fluid analysis, genetics). Responses were analyzed descriptively.
Results:
Of the 22 respondents (58%), all reported the capability to perform neuropsychological testing, MRI,…
